[go: up one dir, main page]

MX2022007634A - Inhibidores de egfr. - Google Patents

Inhibidores de egfr.

Info

Publication number
MX2022007634A
MX2022007634A MX2022007634A MX2022007634A MX2022007634A MX 2022007634 A MX2022007634 A MX 2022007634A MX 2022007634 A MX2022007634 A MX 2022007634A MX 2022007634 A MX2022007634 A MX 2022007634A MX 2022007634 A MX2022007634 A MX 2022007634A
Authority
MX
Mexico
Prior art keywords
compound
egfr inhibitors
formula
medicine
pharmaceutically acceptable
Prior art date
Application number
MX2022007634A
Other languages
English (en)
Inventor
Bernd Kuhn
Yvonne Alice Nagel
Georg Jaeschke
Antonio Ricci
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2022007634A publication Critical patent/MX2022007634A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La solicitud proporciona un compuesto que tiene la Fórmula general (I) (ver Fórmula) (I) o una sal farmacéuticamente aceptable de este, composiciones que incluyen el compuesto y métodos de uso del compuesto. El compuesto de Fórmula (I) se puede usar como un medicamento.
MX2022007634A 2019-12-20 2020-12-18 Inhibidores de egfr. MX2022007634A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19218403 2019-12-20
PCT/EP2020/086914 WO2021123084A1 (en) 2019-12-20 2020-12-18 Egfr inhibitors

Publications (1)

Publication Number Publication Date
MX2022007634A true MX2022007634A (es) 2022-07-19

Family

ID=69411052

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007634A MX2022007634A (es) 2019-12-20 2020-12-18 Inhibidores de egfr.

Country Status (18)

Country Link
US (1) US20230034696A1 (es)
EP (1) EP4076664B1 (es)
JP (1) JP7737991B2 (es)
KR (1) KR20220118426A (es)
CN (1) CN114867531B (es)
AR (1) AR120799A1 (es)
AU (1) AU2020405326A1 (es)
BR (1) BR112022011690A2 (es)
CA (1) CA3160534A1 (es)
CL (1) CL2022001353A1 (es)
CO (1) CO2022006965A2 (es)
CR (1) CR20220255A (es)
IL (1) IL292104A (es)
MX (1) MX2022007634A (es)
PE (1) PE20221768A1 (es)
PH (1) PH12022551241A1 (es)
TW (1) TW202136263A (es)
WO (1) WO2021123084A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113966335B (zh) 2019-06-21 2024-08-02 豪夫迈·罗氏有限公司 用于治疗癌症的egfr抑制剂
KR20220100619A (ko) 2019-11-11 2022-07-15 다나-파버 캔서 인스티튜트 인크. 알로스테릭(allosteric) EGFR 억제제 및 이의 사용 방법
JP7746259B2 (ja) 2019-12-20 2025-09-30 ヌエヴォリューション・アクティーゼルスカブ 核内受容体に対して活性の化合物
AU2020405170A1 (en) 2019-12-20 2022-06-30 Mirati Therapeutics, Inc. SOS1 inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015095807A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of egfr and erk inhibitors
HK1252693A1 (zh) * 2015-06-30 2019-05-31 Dana Farber Cancer Institute, Inc. Egfr抑制剂及其使用方法
FR3041640B1 (fr) * 2015-09-30 2019-05-17 Les Laboratoires Servier NOUVEAUX DERIVES DE PYRROLO[2,3-d]PYRIMIDINE, LEUR PROCEDE DE PREPRATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
GB201519644D0 (en) * 2015-11-06 2015-12-23 Univ Southampton Therapy and pharmaceutical composition
AU2017345574A1 (en) * 2016-10-19 2019-05-23 United States Government As Represented By The Department Of Veterans Affairs Compositions and methods for treating cancer
TW201834651A (zh) * 2016-12-22 2018-10-01 瑞士商赫孚孟拉羅股份公司 化合物
AR113299A1 (es) * 2017-06-02 2020-04-08 Hoffmann La Roche Compuestos de isoindolina
TW201945357A (zh) * 2018-02-05 2019-12-01 瑞士商赫孚孟拉羅股份公司 化合物
WO2019183523A1 (en) * 2018-03-23 2019-09-26 Genentech, Inc. Hetero-bifunctional degrader compounds and their use as modulators of targeted ubiquination (vhl)
PE20211388A1 (es) * 2018-06-29 2021-07-27 Hoffmann La Roche Compuestos

Also Published As

Publication number Publication date
AU2020405326A1 (en) 2022-05-12
BR112022011690A2 (pt) 2022-09-06
EP4076664B1 (en) 2023-08-30
IL292104A (en) 2022-06-01
CN114867531A (zh) 2022-08-05
PE20221768A1 (es) 2022-11-11
CL2022001353A1 (es) 2023-02-17
EP4076664A1 (en) 2022-10-26
CN114867531B (zh) 2024-03-22
EP4076664C0 (en) 2023-08-30
US20230034696A1 (en) 2023-02-02
PH12022551241A1 (en) 2023-10-09
KR20220118426A (ko) 2022-08-25
CO2022006965A2 (es) 2022-06-10
CR20220255A (es) 2022-07-11
AR120799A1 (es) 2022-03-16
JP7737991B2 (ja) 2025-09-11
JP2023506809A (ja) 2023-02-20
WO2021123084A1 (en) 2021-06-24
TW202136263A (zh) 2021-10-01
CA3160534A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
CL2022001529A1 (es) Nuevos derivados de metilquinazolinona
CO2022010098A2 (es) Inhibidores de proteínas kras mutantes
CL2022001353A1 (es) Inhibidores de egfr
MX2023011675A (es) Beta-hidroxietilaminas heteroaril sustituidas para su uso en el tratamiento de hiperglucemia.
JOP20220008A1 (ar) مثبطات parp1
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
CO2017009891A2 (es) Inhibidores de inhibidores del factor beta de crecimiento de transformación (tgf-beta)
CL2022001492A1 (es) Nuevos inhibidores de braf como rompedores de la paradoja
MX2023000418A (es) Fluorofenil beta-hidroxietilaminas y su uso en el tratamiento de la hiperglucemia.
AR077629A1 (es) Mimetico de smac
MX381041B (es) Compuesto cíclico tipo cumarina como inhibidor de mek y su uso.
MX392213B (es) Composiciones farmacéuticas que comprenden sales de glicopirrolato y 1,1-difluoroetano.
MX2019004626A (es) Compuesto de piridona como inhibidor de c-met.
AR107864A1 (es) ÁCIDO 7a,11b-DIHIDROXI-6a-ETIL-5b-COLAN-24-OICO Y COMPOSICIONES FARMACÉUTICAS
CY1126067T1 (el) Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30)
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
AR102981A1 (es) Inhibidores de la necrosis celular y métodos de preparación de los mismos
MX2020004694A (es) Composiciones farmaceuticas inyectables de isoxazolina y su uso contra la infestacion de parasitos.
SV2018005702A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
CL2022000725A1 (es) Inhibidor de irak y método de preparación para el mismo y uso del mismo
MX2019004232A (es) Compuestos terapéuticos y métodos para utilizarlos.
SV2018005701A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
AR091888A1 (es) Compuestos de urea y su uso como inhibidores de enzimas
MX2021009261A (es) Compuesto de fluorovinilbenzamida como inmunomodulador pd-l1.
MX2022008016A (es) Compuesto antagonista de pd-l1.